Global health equity is no longer an abstract ambition; it sits firmly at the centre of the agendas of the World Health Organization (WHO), Gavi, UNICEF and leading global health NGOs. From pandemic preparedness to routine immunisation and advanced biologics, it's becoming clear that life-saving medicines must reach patients everywhere, not only where infrastructure is strongest.
However, access does not end with regulatory approval, procurement agreements or funding commitments. It depends on whether a medicine can physically and safely travel from manufacturing site to patient. One of the most critical, and often overlooked, enablers of that journey is the reliability of the global pharmaceutical cold chain. Without it, access remains theoretical.
Innovation cannot deliver equity alone
The importance of reliable distribution becomes even clearer when viewed against the backdrop of pharmaceutical innovation. Today, an estimated 40–60 percent of all pharmaceuticals require temperature-controlled logistics to maintain safety and efficacy during transport and storage. That proportion continues to rise as biologics, gene therapies and cell therapies represent an increasing share of the global pipeline, and nearly all of them are highly temperature-sensitive.
These therapies are transforming outcomes in oncology, rare diseases, autoimmune disorders and infectious disease. Yet their promise depends on strict environmental control. A deviation of just 1–2°C can significantly degrade sensitive products such as vaccines, insulin and biologics, while advanced cell and gene therapies often require temperature ranges between -60°C and -150°C. As a result, delivery timelines are increasingly being measured in hours rather than days.
When the cold chain breaks, equity breaks
This growing fragility exposes a persistent vulnerability within global distribution systems. Despite advances in packaging and monitoring, around 12 percent of pharmaceutical shipments still experience temperature excursions, meaning exposure outside their validated range. For vaccines, the challenge is even more acute, with the WHO estimating that up to 50 percent are compromised each year due to failures in temperature control and logistics.
The consequences extend well beyond financial loss, although the industry is estimated to lose $35 billion annually due to cold chain breakdowns. When temperature control fails, doses may be discarded, treatment schedules disrupted, scarce healthcare resources wasted and public trust in health systems undermined. In some cases, patients may miss their window for life-saving therapy altogether.
In high-income markets, buffers and redundancies can sometimes absorb these losses. In lower-resource settings, however, there is far less margin for error. Replacement shipments may take weeks, infrastructure gaps amplify risk and every lost dose carries greater consequences. Under these conditions, unreliable cold chain integrity does not merely create inefficiency – it fuels healthcare inequality.
Infrastructure is the missing link in equity conversations
Recognizing this vulnerability shifts the focus from products to systems. WHO and global health NGOs have rightly prioritized financing, manufacturing capacity, regulatory harmonization and last-mile healthcare delivery. Yet reliable temperature-controlled logistics is foundational infrastructure, as critical to health outcomes as roads, ports and power grids are to economic development.
Cold chain failures can occur at multiple points – on airport aprons, during customs delays, in extreme climates or through handling errors – and knowledge gaps persist across parts of the logistics ecosystem. Many handlers and transport providers still lack sufficient training and awareness around temperature-sensitive pharmaceuticals, leading to preventable product loss.
At the same time, climate change, geopolitical instability and disrupted trade routes are introducing new volatility into global supply chains, while regulators are tightening expectations around traceability, validation and data integrity. The standard is shifting from reactive problem-solving to demonstrable end-to-end control.
For equitable access to become sustainable, access to medicines must be matched by access to reliable, validated cold chain systems capable of withstanding disruption.
From reactive logistics to proactive resilience
Meeting this expectation requires a shift in mindset. Historically, parts of the industry relied heavily on passive packaging solutions, which can be cost-effective for short distances but remain vulnerable to delays, extreme weather and handling variability. As therapies become more sensitive and higher in value, such approaches offer diminishing tolerance for risk.
The industry is shifting decisively toward active, risk‑aware management models that prioritise prevention rather than reaction. Real-time monitoring, predictive analytics and early-warning systems enable stakeholders to track shipments continuously, identify potential threats and intervene before product quality is compromised. This shift is reinforced by the World Health Organization’s 2025 Vaccine Shipping Guidelines, which introduce a new “Advanced Active” category for temperature‑controlled packaging – setting a higher global benchmark for vaccine logistics. These guidelines are critical for vaccine manufacturers seeking to meet the most rigorous standards of quality, safety, and regulatory compliance.
When manufacturers have confidence in transport reliability, they are more willing to expand distribution to emerging markets. When governments and NGOs trust that temperature integrity can be maintained, immunisation and treatment programmes can scale more predictably. When data is transparent and verifiable, regulatory confidence strengthens cross-border collaboration.
A shared responsibility
Achieving that reliability depends on collective action. The pharmaceutical cold chain operates as a shared ecosystem in which manufacturers, airlines, freight forwarders, airports, cold chain solution providers and regulators all play interdependent roles. No single organization can guarantee integrity alone, making collaboration, standardization and continuous training essential at every handover.
As advanced therapies expand and global health initiatives push for broader geographic inclusion in clinical trials, product launches and routine access programmes, the tolerance for failure continues to shrink. Equitable access is therefore not achieved at the point of approval; it is realized only when a therapy reaches the patient safely, in full potency and without avoidable delay.
The real cost of getting it wrong
Ultimately, the stakes are measured not only in financial terms but in human outcomes. A single temperature deviation can undo years of research, millions in investment and, most critically, a patient’s chance of timely treatment. In the context of global vaccination campaigns or rare disease therapies, that loss may not be easily recoverable.
If global health equity is truly the objective, reliable cold chain infrastructure must be recognized as a central pillar of delivery. When temperature control fails, access falters – and when access falters, equity itself is compromised.